13F Holdings
中文EN

CAPR CAPRICOR THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1133869 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-11.5%
TTM net income YoY-81.6%
TTM EPS YoY-38.6%
Revenue 3-yr CAGR349.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-191.1%
Net margin-181.7%
FCF margin-184.8%
EBITDA margin-184.7%

Returns

ROE-48.2%
ROA-35.3%
ROIC (approx.)-47.3%
Asset turnover0.19x

Leverage & solvency

Liabilities / assets14.7%
Debt / equity0.00x
Current ratio7.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue5.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$11.13M
R&D expense$29.56M$28.87M$27.38M$23.13M$20.36M$22.05M$18.92M$14.55M
SG&A expense$15.12M$14.08M$9.40M$6.02M$5.92M$5.67M$6.07M$4.27M
Operating income-$44.68M-$42.95M-$36.77M-$29.16M-$26.28M-$27.72M-$24.98M-$7.70M
Pretax income-$42.66M-$40.73M-$33.94M-$30.17M-$24.57M-$25.91M-$24.39M—
Income tax$0$1,600$0$0$0$1,600$0—
Net income-$42.66M-$40.73M-$33.94M-$30.17M-$24.57M-$25.91M-$24.39M-$7.12M
EBITDA-$43.78M-$42.38M-$36.24M-$28.65M-$25.79M-$27.23M-$24.58M-$7.32M
EPS (basic)-0.73-0.70-0.59—-0.54-0.57-0.53—
EPS (diluted)-0.73-0.70-0.59—-0.54-0.57-0.53—
Weighted avg. shares (diluted)58.13M57.93M57.43M—45.72M45.71M45.64M—
Balance sheet
Cash & equivalents$44.28M$20.94M$105.42M$287.85M$19.51M$23.24M$28.79M$11.29M
Short-term investments$153.30M$217.00M$173.19M$30.28M$79.06M$99.56M$115.98M$140.23M
Current assets$202.25M$242.13M$283.09M$322.94M$100.95M$124.13M$146.25M$163.39M
PP&E, net$37.61M$36.35M$28.50M$18.31M$11.07M$8.00M$6.13M$5.56M
Total assets$330.37M$368.74M$326.28M$355.95M$126.44M$133.57M$153.77M$170.48M
Current liabilities$29.90M$32.96M$33.64M$35.84M$28.15M$28.40M$22.34M$21.03M
Total liabilities$120.61M$122.52M$47.58M$50.16M$42.57M$28.59M$26.12M$25.02M
Shareholders' equity$209.76M$246.22M$278.70M$305.79M$83.87M$104.98M$127.65M$145.46M
Shares outstanding58.14M58.11M57.66M57.37M45.72M45.71M45.68M45.58M
Cash flow statement
Operating cash flow-$35.69M-$31.49M-$29.25M-$23.57M-$19.69M-$20.12M-$6.43M-$14.80M
Capital expenditure$1.81M$4.06M$5.12M$1.66M$55,843$287,738$896,007$488,798
Free cash flow-$37.50M-$35.55M-$34.38M-$25.23M-$19.74M-$20.41M-$7.33M-$15.29M
Investing cash flow$59.90M-$48.76M-$154.64M$43.09M$15.95M$14.55M$23.89M-$123.38M
Financing cash flow$88,700-$4.24M$1.47M$248.82M$6,950$19,580$50,354$81.09M
Depreciation & amortization$900,989$561,845$534,670$502,587$494,725$486,278$405,450$375,705
Stock-based compensation———$3.84M$4.00M$3.65M$5.74M$2.30M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.